GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pfizer Inc (BUE:PFE) » Definitions » Debt-to-EBITDA

Pfizer (BUE:PFE) Debt-to-EBITDA : 2.30 (As of Sep. 2024)


View and export this data going back to . Start your Free Trial

What is Pfizer Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Pfizer's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ARS9,218,899 Mil. Pfizer's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ARS54,100,557 Mil. Pfizer's annualized EBITDA for the quarter that ended in Sep. 2024 was ARS27,575,905 Mil. Pfizer's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was 2.30.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Pfizer's Debt-to-EBITDA or its related term are showing as below:

BUE:PFE' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.85   Med: 2.61   Max: 7.41
Current: 4.82

During the past 13 years, the highest Debt-to-EBITDA Ratio of Pfizer was 7.41. The lowest was 0.85. And the median was 2.61.

BUE:PFE's Debt-to-EBITDA is ranked worse than
80.18% of 656 companies
in the Drug Manufacturers industry
Industry Median: 1.67 vs BUE:PFE: 4.82

Pfizer Debt-to-EBITDA Historical Data

The historical data trend for Pfizer's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pfizer Debt-to-EBITDA Chart

Pfizer Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.73 2.89 1.20 0.85 7.41

Pfizer Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.49 -10.00 2.89 7.14 2.30

Competitive Comparison of Pfizer's Debt-to-EBITDA

For the Drug Manufacturers - General subindustry, Pfizer's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pfizer's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pfizer's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Pfizer's Debt-to-EBITDA falls into.



Pfizer Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Pfizer's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(3734906.003 + 21840139.02) / 3450077.003
=7.41

Pfizer's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(9218899.095 + 54100556.622) / 27575904.788
=2.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.


Pfizer  (BUE:PFE) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Pfizer Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Pfizer's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Pfizer Business Description

Address
66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.